Please login to the form below

Not currently logged in
Email:
Password:

Darzalex

This page shows the latest Darzalex news and features for those working in and with pharma, biotech and healthcare.

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Unsure on efficacy, NICE passes J&J’s Darzalex to CDF

Unsure on efficacy, NICE passes J&J’ s Darzalex to CDF. The bone marrow cancer therapy is now temporarily approved as a fourth-line treatment. ... Johnson &Johnson’s multiple myeloma drug Darzalex has failed to win over NICE for a second time, but

Latest news

  • J&J files would-be prostate cancer blockbuster in US J&J files would-be prostate cancer blockbuster in US

    That view was echoed by Jefferies Jeffrey Holford, who says J&J’s so-called TIRADE products - Tremfya (guselkumab) for psoriasis, cancer drug Imbruvica (ibrutinib), anticoagulant rivaroxaban (Xarelto), apalutamide, Darzalex (daratumumab)

  • SMC backtracks on Janssen’s multiple myeloma treatment Darzalex SMC backtracks on Janssen’s multiple myeloma treatment Darzalex

    SMC backtracks on Janssen’ s multiple myeloma treatment Darzalex. Will now recommend the first-in-class treatment after securing a discount. ... counterpart and back Darzalex to be more widely used in England and Wales.

  • Biosimilars eat into J&J's Remicade sales Biosimilars eat into J&J's Remicade sales

    multiple myeloma therapy Darzalex (daratumumab) almost tripling to $299m compared to a year ago, thanks to expanded indications including second-line use.

  • Redefining launch excellence in 2017 Redefining launch excellence in 2017

    For example, Janssen’s Darzalex (daratumumab) was granted accelerated approval based on response rates for patients with multiple myeloma who have received at least three prior lines of therapy.

  • Amgen's Kyprolis tops Velcade in myeloma trial Amgen's Kyprolis tops Velcade in myeloma trial

    Multiple myeloma is becoming increasingly competitive, however, thanks to new launches such as Bristol-Myers Squibb's Empliciti (elotuzumab), Novartis' Farydak (panobinostat) and Johnson &Johnson's Darzalex (daratumumab).

More from news
Approximately 8 fully matching, plus 14 partially matching documents found.

Latest Intelligence

  • Europe vs the US: New drug product approvals Europe vs the US: New drug product approvals

    Among the noteworthy orphan approvals are Exondys 51 (for the treatment of Duchenne muscular dystrophy, only approved in the US), Darzalex (for the treatment of multiple myeloma, approved in the US

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Rainmaker Healthcare Communications

Rainmaker is an independent, award-winning communications agency with offices in London and Atlanta. Our experience across pharmaceuticals, generics, OTC, medical...

Latest intelligence

Island
Pharma’s isolated islands of innovation
With service design and technology often failing the patient, why perspective on improving outcomes need to change...
Uncertainty, austerity and Brexit
What does it mean for the life science sector?...
The Holy Grail of HCP Access
This is the data you need to gain access....

Infographics